drugset / Trial / NCT06731140
Reverse HER2-negative Immune Resistant Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, open-label study evaluating the efficacy and safety of combined treatment (retinoic acid) with immune checkpoint inhibitor in HER2-negative breast cancer patients who progressed during previous immune checkpoint inhibitors.
Timeline
- Start
- 2025-02-12
- Primary completion
- 2026-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Isotretinoin | Other / unclassified | 20 mg | Oral |